Market Overview
The global glycomics market was valued at USD 1.7 Billion in 2024 and is projected to reach USD 4.5 Billion by 2033, exhibiting a CAGR of 10.61% during the forecast period from 2025 to 2033. The market growth is supported by rising chronic disease prevalence, advancements in glycoengineering, and growing involvement of contract research organizations (CROs) in drug and biologics development. North America dominates with over 39.1% market share, driven by robust biotechnology advancements.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Glycomics Market Key Takeaways
- Current Market Size: USD 1.7 Billion in 2024
- CAGR: 10.61% during 2025-2033
- Forecast Period: 2025-2033
- North America leads the market with a share of over 39.1% as of 2024
- The market growth is fueled by the increasing incidence of chronic diseases and expanding focus on glycoengineering techniques
- Demand is driven by an increasing number of contract research organizations (CROs) involved in drug and biologics
- Therapeutic areas such as cancer, cardiovascular, and infectious diseases are major focus areas for glycomics research
Sample Request Link: https://www.imarcgroup.com/Glycomics-Market/requestsample
Market Growth Factors
The glycomics market is fueled by progressive developments in biotechnology, together with growing acceptance of the role of glycans in human health and disease. Scientific evidence about the role of glycans in cancer, infectious, and neurological diseases is key to growing interest in glycomics technologies. Biopharmaceutical firms are heavily investing in glycan based pharmaceutical agents, encouraging faster growth of the glycomics market. The emerging use of biologics such as monoclonal antibodies and glycoproteins emphasizes the need for glycan analysis in order to develop medicines.
An increasing number of activities related to research and development (R&D) is propelling the glycomics market forward. Global expenditures on R&D reached USD 2.6 trillion in 2021, with a focus on glycomics in medical discovery, personalized medicines, and diagnosis. There has been collaborative effort among academia, businesses, and research organizations, which is spurring innovation and speeding up the development of products based on glycomics.
Personalized medicine or precision medicine is also driving the glycomics market due to greater investments. Investments by the US Precision Medicine Initiative of USD 215 Million in 2016 and again by USD 54 Million more in 2023 display the increasing investments by countries for precision medicine or personalized medicine. Glycans have shown promising usage as biomarkers for both diagnosis and prognosis, and methods like glycan microarray profiling have simplified the procedure to identify disease-specific glycan signatures.
Market Segmentation
Product:
- Enzymes: Comprising glycosidases, glycosyltransferases, neuraminidases, sialyltransferases; enzymes hold a 29.6% market share by facilitating glycan analysis and manipulation, enzymatic cleavage from glycoproteins, and enabling complex glycomics workflows.
- Instruments: Include mass spectrometers, HPLC, MALDI-TOF, array systems, crucial for advanced glycomics research.
- Kits: Glycan labeling kits, purification kits, release kits, supporting diverse glycomic sample preparations.
- Reagents: Glycoproteins, monosaccharides, oligosaccharides, essential for glycomics experimental protocols.
Application:
- Drug Discovery and Development: Holds the largest share at 43.6%, pivotal for understanding glycans in disease mechanisms, therapeutic targeting, and drug efficacy.
- Diagnostics: Utilized in biomarker discovery and disease diagnosis.
- Others: Other varied glycomics applications.
End User:
- Academic and Research Institutes: Largest share at 38.7%, driving scientific research and innovation with advanced labs and interdisciplinary collaborations.
- Pharmaceutical and Biotechnology Companies: Engaged in product development and commercialization.
- Contract Research Organizations (CROs): Support research and development activities in glycomics.
Regional Insights
North America dominates the glycomics market with a 39.1% share in 2024. The region benefits from renowned academic institutions, research organizations, and biotech firms with robust infrastructure and collaborations. A well-developed healthcare and biopharmaceutical sector drives demand for glycomics in drug discovery and personalized medicine. Favorable regulations and strong intellectual property protections further support innovation and commercialization of glycomics-based products.
Recent Developments & News
- December 2024: GlycoNet partnered with Michael Smith Health Research BC, backed by USD 12 million financing including USD 2.3 million for British Columbia teams focusing on chronic illnesses, cancer treatments, and vaccination reactions.
- March 2024: Bruker Corporation advanced immunopeptidomics and glycoproteomics with CCS-enabled 4D proteomics workflows, machine learning algorithms, and glyco-PASEF® technology.
- February 2024: GlycanAge secured USD 4.2 million seed funding led by LAUNCHub Ventures and Kadmos Capital to develop glycan biomarkers for personalized preventative healthcare.
- January 2024: Navinci Diagnostics and Vector Laboratories collaborated to develop innovative biomarker discovery techniques leveraging glycomic research.
Key Players
- Agilent Technologies Inc.
- Asparia Glycomics
- Bruker Corporation
- Danaher Corporation
- Dextra Laboratories Limited (New Zealand Pharmaceuticals Limited)
- Merck KGaA
- New England Biolabs
- RayBiotech Life Inc.
- Shimadzu Corporation
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- Waters Corporation
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request for customization: https://www.imarcgroup.com/request?type=report&id=5689&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
Comments (0)